Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Ortmann and Kentet al. show that the order of acquisition of Janus kinase 2 (JAK2) mutations and tet methylcytosine dioxygenase 2 (TET2) mutations in myeloproliferative neoplasms can affect tumour cell biology and clinical phenotypes.
Alberto Mantovani and colleagues have found that loss of a regulator of the complement cascade, penatraxin 3 (PTX3), accelerates tumour development in mice owing to a complement- and macrophage-mediated immune response.
Polaket al. have found that the mutation profile of a given cancer can be predicted from the epigenomic signature of the cell type from which that cancer was most likely to have originated.
Marzecet al. have described a new telomere-dependent mechanism by which genomic instability and chromosomal translocations can be induced in cancer cells that use alternative lengthening of telomeres for telomere maintenance.
Haematological malignancies have provided both initial proofs of concept and an informative testing ground for various immune-based cancer therapeutics. The immune-cell origin of many of the blood malignancies provides a unique opportunity both to understand the mechanisms of cancer immune responsiveness and immune evasion, and to exploit the unique therapeutic opportunities they provide.
Caveolar lipid rafts are distinct regions of the cell membrane that can mediate diverse signalling events, including the regulation of autophagy, responses to oxidative stress and metabolism. What are the implications of caveolae in cancer cells and associated stromal cells?
This Opinion article advocates therapeutically targeting the niches that harbour dormant disseminated tumour cells in order to make them susceptible to cytotoxic agents. Similar strategies have sensitized leukaemic cells and latent HIV to therapy, and such an approach might delay or even prevent metastasis.
There is evidence that African-American women with triple-negative breast cancer (TNBC) have worse clinical outcomes than women of European descent with TNBC. However, it is unclear whether survival differences persist after adjusting for health disparities. Understanding the relative contributions of biology and disparities is crucial for improving the poor survival of African-American women with TNBC.
